|
|
Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort |
|---|---|
| Author: | af Björkesten, Clas-Göran1; Ilus, Tuire2; Hallinen, Taru3; |
| Organizations: |
1Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki 2Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere 3ESiOR Oy, Kuopio
4Department of Internal Medicine, Kanta-Häme Central Hospital, Hämeenlinna
5Department of Gastroenterology, North Karelia Central Hospital, Joensuu 6Department of Medicine, Division of Gastroenterology, Oulu University Hospital, Oulu 7Department of Internal Medicine, Central Finland Central Hospital, Jyväskylä 8Department of Internal Medicine, Satakunta Central Hospital, Pori 9Department of Internal Medicine, Vaasa Central Hospital, Vaasa 10Division of Gastroenterology, Department of Medicine, Turku University Hospital, Turku 11Department of Internal Medicine, Kuopio University Hospital, Kuopio 12Department of Internal Medicine, Kainuu Central Hospital, Kajaani 13Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti 14Department of Internal Medicine, Turku University Hospital, Salo Hospital, Salo 15Department of Internal Medicine, Central Ostrobothnia Central Hospital, Kokkola, Finland 16Medical Affairs, Janssen Cilag AB, Solna, Sweden 17Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark 18Janssen Cilag Limited, EMEA HEMAR, High Wycombe, UK 19Medical Affairs, Janssen Cilag Oy, Espoo, Finland |
| Format: | article |
| Version: | published version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 0.7 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe202101202190 |
| Language: | English |
| Published: |
Wolters Kluwer,
2020
|
| Publish Date: | 2021-01-20 |
| Description: |
AbstractObjective: Long-term evidence on ustekinumab treatment response and persistence in patients with Crohn’s disease in a real-world setting is scarce. We performed a retrospective nationwide chart review study of long-term clinical outcomes in Crohn’s disease patients treated with ustekinumab. Methods: The study was conducted in 17 Finnish hospitals and included adult Crohn’s disease patients who received an initial intravenous dose of ustekinumab during 2017–2018. Disease activity data were collected at baseline, 16 weeks, and 1 year from health records. Results: The study included 155 patients. The disease was stricturing or penetrating in 69 and 59% had prior Crohn’s disease-related surgeries, and 97% had a treatment history of at least one biologic agent. Of 93 patients with ≥1 year of follow-up, 77 (83%) were still on ustekinumab at 1 year. In patients with data available, from baseline to the 1-year follow-up the simple endoscopic score for Crohn’s disease (SES-CD) decreased from 10 to 3 (P = 0.033), C-reactive protein from 7 to 5 mg/L, (P < 0.001) and faecal calprotectin from 776 to 305 μg/g (P < 0.001). Conclusions: Ustekinumab treatment in patients with highly refractory Crohn’s disease resulted in high long-term treatment persistence and significantly reduced disease activity, assessed with objective markers for intestinal inflammatory activity. see all
|
| Series: |
European journal of gastroenterology & hepatology |
| ISSN: | 0954-691X |
| ISSN-E: | 1473-5687 |
| ISSN-L: | 0954-691X |
| Volume: | 32 |
| Issue: | 12 |
| Pages: | 1507 - 1513 |
| DOI: | 10.1097/MEG.0000000000001831 |
| OADOI: | https://oadoi.org/10.1097/MEG.0000000000001831 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3121 General medicine, internal medicine and other clinical medicine |
| Subjects: | |
| Funding: |
This study was supported by Janssen-Cilag Oy (Finland). |
| Copyright information: |
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
|
https://creativecommons.org/licenses/by-nc-nd/4.0/ |